A review on the relationship between SGLT2 inhibitors and cancer

International Journal of Endocrinology

Volumn 2014, Issue , 2014, Pages

  Lin, Hao Wen ^a   Tseng, Chin Hsiao ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2;

BLADDER CANCER; BREAST CANCER; CANCER GRADING; CANCER RISK; CLINICAL EFFECTIVENESS; DIABETES MELLITUS; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ETHNICITY; FOOD AND DRUG ADMINISTRATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TESTIS CANCER; TREATMENT DURATION;

EID: 84921480876     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2014/719578     Document Type: Review

References (51)

1. G. Danaei,M.M. Finucane, Y. Lu et al., "National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: Systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants," The Lancet, vol. 378, no. 9785, pp. 31-40, 2011.
2. S. Wild, G. Roglic, A. Green, R. Sicree, and H. King, "Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030," Diabetes Care, vol. 27,no. 5, pp. 1047-1053, 2004.
3. Y. Ohkubo, H. Kishikawa, E. Araki et al., "Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study," Diabetes Research and Clinical Practice, vol. 28, no. 2, pp. 103-117, 1995.
4. UK Prospective Diabetes Study (UKPDS) Group, "Intensive blood-glucose controlwith sulphonylureas or insulin compared with conventional treatment and risk of complications in patientswith type 2 diabetes (UKPDS 33)," The Lancet, vol. 352, no. 9131, pp. 837-853, 1998.
5. R. R. Holman, S. K. Paul, M. A. Bethel,D. R.Matthews, andH. A. W. Neil, "10-Year follow-up of intensive glucose control in type 2 diabetes," New England Journal of Medicine, vol. 359, no. 15, pp. 1577-1589, 2008.
6. E. M. Wright, "Renal Na(+)-glucose cotransporters," American Journal of Physiology-Renal Physiology, vol. 280, no. 1, pp. F10-F18, 2001.
7. M. Bhartia, A. A. Tahrani, andA.H.Barnett, "SGLT-2 inhibitors in development for type 2 diabetes treatment," Review of Diabetic Studies, vol. 8, no. 3, pp. 348-354, 2011.
8. E. Ferrannini and A. Solini, "SGLT2 inhibition in diabetes mellitus: Rationale and clinical prospects," Nature Reviews Endocrinology, vol. 8, no. 8, pp. 495-502, 2012.
9. E. M. Wright and E. Turk, "The sodium/glucose cotransport family SLC5," Pflugers Archiv, vol. 447, no. 5, pp. 510-518, 2004.
10. J. R. L. Ehrenkranz, N. G. Lewis, C. R. Kahn, and J. Roth, "Phlorizin: A review," Diabetes/Metabolism Research and Reviews, vol. 21, no. 1, pp. 31-38, 2005.
11. J. E. Gerich and A. Bastien, "Development of the sodiumglucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with Type 2 diabetes mellitus," Expert Review of Clinical Pharmacology, vol. 4, no. 6, pp. 669-683, 2011.
12. J. Rosenstock, N. Aggarwal, D. Polidori et al., "Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes," Diabetes Care, vol. 35, no. 6, pp. 1232-1238, 2012.
13. S.A.Nisly,D.M. Kolanczyk, andA.M.Walton, "Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes,"The American Journal of Health-System Pharmacy, vol. 70, no. 4, pp. 311-319, 2013.
14. U.S. Food and Drug Administration, "FDA Briefing Document, NDA 204042 Canagliflozin tablets. Advisory Committee Meeting: 2013," http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM334550.pdf.
15. E. Ferrannini, A. Berk, S. Hantel et al., "Long-term safety and efficacy of empagliflozin , sitagliptin , andmetformin: An activecontrolled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes," Diabetes Care, vol. 36, no. 12, pp. 4015-4021, 2013.
16. J. Rosenstock, L. J. Seman, A. Jelaska et al., "Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia," Diabetes, Obesity and Metabolism, vol. 15, no. 12, pp. 1154-1160, 2013.
17. R. F. Rosenwasser, S. Sultan, D. Sutton, R. Choksi, and B. J. Epstein, "SGLT-2 inhibitors and their potential in the treatment of diabetes," Journal of Diabetes, Metabolic Syndrome and Obesity, vol. 6, pp. 453-467, 2013.
18. N. Inagaki, K. Kondo, T. Yoshinari, N. Maruyama, Y. Susuta, and H. Kuki, "Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, 12-week study," Diabetes, Obesity and Metabolism, vol. 15, no. 12, pp. 1136-1145, 2013.
19. S.Cangoz, Y. Y. Chang, S. J. Chempakaseril et al., "The kidney as a newtarget for antidiabetic drugs: SGLT2 inhibitors," Journal of Clinical Pharmacy andTherapeutics, vol. 38, no. 5, pp. 350-359, 2013.
20. U.S. Food and Drug Administration, "FDA background document, BMS-512148NDA202293 dapagliflozin," in Proceedings of the Endocrinologic&Metabolic Drug Advisory CommitteeMeeting, 2013, http://www.fda.gov/downloads/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm378079.pdf.
21. X.-Q. Yang, C. Xu, Y. Sun, and R.-F. Han, "Diabetes mellitus increases the risk of bladder cancer: An updated meta-analysis," Asian Pacific Journal of Cancer Prevention, vol. 14, no. 4, pp. 2583-2589, 2013.
22. H. Fang, B. Yao, Y. Yan et al., "Diabetes mellitus increases the risk of bladder cancer: An updated meta-analysis of observational studies," Diabetes Technology & Therapeutics, vol. 15, no. 11, pp. 914-922, 2013.
23. Z. Zhu, X. Wang, Z. Shen, Y. Lu, S. Zhong, and C. Xu, "Risk of bladder cancer in patients with diabetes mellitus: An updated meta-analysis of 36 observational studies," BMC Cancer, vol. 13, article 310, 2013.
24. C.-H. Tseng, C.-K. Chong, C.-P. Tseng, and T.-T. Chan, "Agerelated risk of mortality from bladder cancer in diabetic patients: A 12-year follow-up of a national cohort in Taiwan," Annals of Medicine, vol. 41, no. 5, pp. 371-379, 2009.
25. C.-H. Tseng, "Diabetes and risk of bladder cancer: A study using the National Health Insurance database in Taiwan," Diabetologia, vol. 54, no. 8, pp. 2009-2015, 2011.
26. C.-H. Tseng, "Benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients: A populationbased cohort study using the National Health Insurance in Taiwan," BMC Cancer, vol. 13, article 7, 2013.
27. C.-H. Tseng, "Pioglitazone and bladder cancer: A populationbased study of Taiwanese," Diabetes Care, vol. 35, no. 2, pp. 278-280, 2012.
28. R.Mamtani, K.Haynes,W. B. Bilker et al., "Association between longer therapy with thiazolidinediones and risk of bladder cancer: A cohort study," Journal of the National Cancer Institute, vol. 104, no. 18, pp. 1411-1421, 2012.
29. L. Azoulay, H. Yin, K. B. Filion et al., "The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: Nested case-control study," BMJ, vol. 344, Article IDe3645, 2012.
30. L. Wei, T. M. Macdonald, and I. S. Mackenzie, "Pioglitazone and bladder cancer: A propensity score matched cohort study," British Journal of Clinical Pharmacology, vol. 75, no. 1, pp. 254-259, 2013.
31. C. H. Tseng, "A review on thiazolidinediones and bladder cancer in human studies," Journal of Environmental Science and Health C, vol. 32, no. 1, pp. 1-45, 2014.
32. J. D. Lewis, A. Ferrara, T. Peng et al., "Risk of bladder cancer among diabetic patients treated with pioglitazone: Interim report of a longitudinal cohort study," Diabetes Care, vol. 34, no. 4, pp. 916-922, 2011.
33. A. Neumann, A. Weill, P. Ricordeau, J. P. Fagot, F. Alla, and H. Allemand, "Pioglitazone and risk of bladder cancer among diabetic patients in France: A population-based cohort study," Diabetologia, vol. 55, no. 7, pp. 1953-1962, 2012.
34. C. H. Tseng, "Metformin may reduce bladder cancer risk in Taiwanese patients with type 2 diabetes," Acta Diabetol, vol. 51, no. 2, pp. 295-303, 2014.
35. U.S. Food and Drug Administration, FDA Briefing Document, NDA 202293Dapagliflozin tablets, 5 and 10mg.Advisory CommitteeMeeting, 2011, http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm262994.pdf.
36. T. P. Reilly, M. J. Graziano, E. B. Janovitz et al., "Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus," Diabetes Therapy, vol. 5, no. 1, pp. 73-96, 2014.
37. D. Jones, "Diabetes field cautiously upbeat despite possible setback for leading SGLT2 inhibitor," Nature Reviews Drug Discovery, vol. 10, no. 9, pp. 645-646, 2011.
38. D. E. Prentice and A. W. Meikle, "A review of drug-induced Leydig cell hyperplasia and neoplasia in the rat and some comparisons with man," Human and Experimental Toxicology, vol. 14, no. 7, pp. 562-572, 1995.
39. F. J. C. Roe, "Relevance for man of the effects of lactose, polyols and other carbohydrates on calcium metabolism seen in rats: A review," Human Toxicology, vol. 8, no. 2, pp. 87-98, 1989.
40. J. Ren, L.R. Bollu, F. Su et al., "EGFR-SGLT1 interaction does not respond to EGFRmodulators, but inhibition of SGLT1 sensitizes prostate cancer cells to EGFR tyrosine kinase inhibitors," Prostate, vol. 73, no. 13, pp. 1453-1461, 2013.
41. M. Perez, J. M. Praena-Fernandez, B. Felipe-Abrio et al., "MAP17 and SGLT1 protein expression levels as prognostic markers for cervical tumor patient survival," PLoS ONE, vol. 8, no. 2, Article ID e56169, 2013.
42. V. F. Casneuf, P. Fonteyne, N. Van Damme et al., "Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival," Cancer Investigation, vol. 26, no. 8, pp. 852-859, 2008.
43. B. Lai, Y. Xiao, H. Pu, Q. Cao, H. Jing, and X. Liu, "Overexpression of SGLT1 is correlated with tumor development and poor prognosis of ovarian carcinoma," Archives of Gynecology and Obstetrics, vol. 285, no. 5, pp. 1455-1461, 2012.
44. Y. Hanabata, Y. Nakajima, K. I. Morita, K. Kayamori, and K. Omura, "Coexpression of SGLT1 and EGFR is associated with tumor differentiation in oral squamous cell carcinoma," Odontology, vol. 100, no. 2, pp. 156-163, 2012.
45. G. F. Guo, Y. C. Cai, B. Zhang et al., "Overexpression of SGLT1 and EGFR in colorectal cancer showing a correlation with the prognosis," Medical Oncology, vol. 28, no. 1, pp. S197-S203, 2011.
46. N. Ishikawa, T. Oguri, T. Isobe, K. Fujitaka, and N. Kohno, "SGLT gene expression in primary lung cancers and their metastatic lesions," Japanese Journal of Cancer Research, vol. 92, no. 8, pp. 874-879, 2001.
47. C.Pelucchi, C. Bosetti, E.Negri,M.Malvezzi, andC.LaVecchia, "Mechanisms of disease: The epidemiology of bladder cancer," Nature Clinical Practice Urology, vol. 3, no. 6, pp. 327-340, 2006.
48. S. Jankovíc and V. Radosavljevíc, "Risk factors for bladder cancer," Tumori, vol. 93, no. 1, pp. 4-12, 2007.
49. R. L. Jacobs, C. T. Lee, and J. E.Montie, "Bladder cancer in 2010 how far have we come?" CA Cancer Journal for Clinicians, vol. 60, no. 4, pp. 244-272, 2010.
50. D. Volanis, T. Kadiyska, A. Galanis, D. Delakas, S. Logotheti, and V. Zoumpourlis, "Environmental factors and genetic susceptibility promote urinary bladder cancer," Toxicology Letters, vol. 193, no. 2, pp. 131-137, 2010.
51. X. Jiang, J. E. Castelao, S. Groshen et al., "Urinary tract infections and reduced risk of bladder cancer in Los Angeles," British Journal of Cancer, vol. 100, no. 5, pp. 834-839, 2009.